UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients

British journal of cancer, 2013-02, Vol.108 (3), p.668-675

2013

Volltextzugriff (PDF)

The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010

Annals of oncology, 2011-06, Vol.22, p.v1-v9

2011

Volltextzugriff (PDF)

A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer

ESMO open, 2022-12, Vol.7 (6), p.100639, Article 100639

2022

Volltextzugriff (PDF)

Comparing the broad socio‐cognitive profile of youth with Williams syndrome and 22q11.2 deletion syndrome

Journal of intellectual disability research, 2017-12, Vol.61 (12), p.1083-1093

2017

Volltextzugriff (PDF)

Safety and antitumor activity of pembrolizumab in patients with advanced microsatellite instability–high (MSI-H) colorectal cancer: KEYNOTE-164

Annals of oncology, 2018-06, Vol.29, p.v107-v107

2018

Volltextzugriff (PDF)

A phase IIa trial to assess the safety and efficacy of BL-8040 and pembrolizumab in patients with metastatic pancreatic adenocarcinoma (PDAC)

Annals of oncology, 2018-10, Vol.29, p.viii402-viii402

2018

Volltextzugriff (PDF)

Treatments and clinical outcomes in stage II colon cancer patients with 12-gene Oncotype DX Colon Recurrence Score® assay-guided therapy: real-world data

ESMO open, 2024-08, Vol.9 (8), p.103648, Article 103648

2024

Volltextzugriff (PDF)

Pembrolizumab for metastatic triple-negative breast cancer (mTNBC): long-lasting responses in the phase Ib KEYNOTE-012 study

European journal of cancer (1990), 2017-02, Vol.72, p.S38-S38

2017

Volltextzugriff (PDF)

Does residual microscopic disease after chemoradiotherapy for locally advanced rectal cancer translate into a good clinical outcome?

Colorectal disease, 2017-03, Vol.19 (3), p.237-242

2017

Volltextzugriff (PDF)

Efficacy of pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high cancers

Annals of oncology, 2017-09, Vol.28, p.v128-v129

2017

Volltextzugriff (PDF)

The neurocognitive outcome of IUGR children born to mothers with and without preeclampsia

The journal of maternal-fetal & neonatal medicine, 2012-11, Vol.25 (11), p.2206-2208

2012

Volltextzugriff (PDF)

Verbal short-term memory span in children: long-term modality dependent effects of intrauterine growth restriction

Journal of child psychology and psychiatry, 2008-12, Vol.49 (12), p.1321-1330

2008

Volltextzugriff (PDF)

Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009

Annals of oncology, 2010-06, Vol.21 (suppl-6), p.vi1-vi10

2010

Volltextzugriff (PDF)

Isolated mild white matter signal changes in preterm infants: a regional approach for comparison of cranial ultrasound and MRI findings

Journal of perinatology, 2014-06, Vol.34 (6), p.476-482

2014

Volltextzugriff (PDF)

Neoadjuvant systemic chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis from colorectal cancer

Annals of oncology, 2017-09, Vol.28, p.v173-v173

2017

Volltextzugriff (PDF)

2073P Medical cannabis: A potential effective treatment for chemotherapy-induced peripheral neuropathy (CIPN)

Annals of oncology, 2023-10, Vol.34, p.S1092-S1092

2023

Volltextzugriff (PDF)

P-290 Mutant allele specific imbalance in RAS as prognostic marker in colorectal cancer

Annals of oncology, 2021-07, Vol.32, p.S195-S196

2021

Volltextzugriff (PDF)

6015 POSTER DISCUSSION An International Consortium in Chemo-refractory Metastatic Colorectal Cancer Patients Shows Cetuximab Efficacy in Patients Harboring HER2 Gene Copy Number Gain

European journal of cancer (1990), 2011, Vol.47, p.S396-S396

2011

Volltextzugriff (PDF)

1626P A novel endoscopic ultrasound guided extended-release siRNA implant targeting KRASG12D/V in localized pancreatic cancer

Annals of oncology, 2023-10, Vol.34, p.S901-S901

2023

Volltextzugriff (PDF)

990O Final results from phase I, first-in-human, dose escalation study of a first-in-class anti-ILT2 antibody, SAR444881, alone and with pembrolizumab or cetuximab, in patients with advanced solid tumors

Annals of oncology, 2024-09, Vol.35, p.S675-S675

2024

Volltextzugriff (PDF)

The rate of the 6174delT founder Jewish mutation in BRCA2 in patients with non-colonic gastrointestinal tract tumours in Israel

British journal of cancer, 2001-02, Vol.84 (4), p.478-481

2001

Volltextzugriff (PDF)

1045P Safety and preliminary clinical activity of JNJ-78306358 (JNJ-358), an HLA-G and CD3 bispecific antibody, for the treatment of advanced stage solid tumor

Annals of oncology, 2023-10, Vol.34, p.S633-S634

2023

Volltextzugriff (PDF)

P-81 Phase 3 study of MK4280A (coformulated favezelimab and pembrolizumab) versus standard of care in previously treated PD-L1–positive metastatic colorectal cancer (mCRC)

Annals of oncology, 2022-06, Vol.33, p.S277

2022

Volltextzugriff (PDF)

27O Interim results of a phase I/II trial of NT219 in combination with cetuximab in patients with advanced/metastatic squamous cell carcinoma of the head and neck (SCCHN)

ESMO open, 2024-02, Vol.9, p.102355, Article 102355

2024

Volltextzugriff (PDF)

524O Initial results of a phase I study of MK-4830, a first-in-class anti–immunoglobulin-like transcript 4 (ILT4) myeloid-specific antibody in patients (pts) with advanced solid tumours

Annals of oncology, 2020-09, Vol.31, p.S462-S462

2020

Volltextzugriff (PDF)

1 – 25 von 591

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(527)
Mit Volltextzugriff
(533)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(588)
Hebräisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(346)
Life Sciences & Biomedicine
(231)
Humans
(212)
Female
(154)
Male
(123)
Biological And Medical Sciences
(102)
Medical Sciences
(91)
Adult
(86)
Technology
(77)
Middle Aged
(65)
Cardiovascular System & Cardiology
(63)
Cardiac & Cardiovascular Systems
(62)
Computer Science
(53)
Physical Sciences
(53)
Aged
(49)
Physics
(47)
Child
(46)
Adolescent
(45)
Computer Science, Theory & Methods
(44)
Computer Science, Information Systems
(41)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients

The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010

A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer

Comparing the broad socio‐cognitive profile of youth with Williams syndrome and 22q11.2 deletion syndrome

Safety and antitumor activity of pembrolizumab in patients with advanced microsatellite instability–high (MSI-H) colorectal cancer: KEYNOTE-164

A phase IIa trial to assess the safety and efficacy of BL-8040 and pembrolizumab in patients with metastatic pancreatic adenocarcinoma (PDAC)

Treatments and clinical outcomes in stage II colon cancer patients with 12-gene Oncotype DX Colon Recurrence Score® assay-guided therapy: real-world data

Pembrolizumab for metastatic triple-negative breast cancer (mTNBC): long-lasting responses in the phase Ib KEYNOTE-012 study

Does residual microscopic disease after chemoradiotherapy for locally advanced rectal cancer translate into a good clinical outcome?

Efficacy of pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high cancers

The neurocognitive outcome of IUGR children born to mothers with and without preeclampsia

Verbal short-term memory span in children: long-term modality dependent effects of intrauterine growth restriction

Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009

Isolated mild white matter signal changes in preterm infants: a regional approach for comparison of cranial ultrasound and MRI findings

Neoadjuvant systemic chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis from colorectal cancer

2073P Medical cannabis: A potential effective treatment for chemotherapy-induced peripheral neuropathy (CIPN)

P-290 Mutant allele specific imbalance in RAS as prognostic marker in colorectal cancer

6015 POSTER DISCUSSION An International Consortium in Chemo-refractory Metastatic Colorectal Cancer Patients Shows Cetuximab Efficacy in Patients Harboring HER2 Gene Copy Number Gain

1626P A novel endoscopic ultrasound guided extended-release siRNA implant targeting KRASG12D/V in localized pancreatic cancer

990O Final results from phase I, first-in-human, dose escalation study of a first-in-class anti-ILT2 antibody, SAR444881, alone and with pembrolizumab or cetuximab, in patients with advanced solid tumors

The rate of the 6174delT founder Jewish mutation in BRCA2 in patients with non-colonic gastrointestinal tract tumours in Israel

1045P Safety and preliminary clinical activity of JNJ-78306358 (JNJ-358), an HLA-G and CD3 bispecific antibody, for the treatment of advanced stage solid tumor

P-81 Phase 3 study of MK4280A (coformulated favezelimab and pembrolizumab) versus standard of care in previously treated PD-L1–positive metastatic colorectal cancer (mCRC)

27O Interim results of a phase I/II trial of NT219 in combination with cetuximab in patients with advanced/metastatic squamous cell carcinoma of the head and neck (SCCHN)

524O Initial results of a phase I study of MK-4830, a first-in-class anti–immunoglobulin-like transcript 4 (ILT4) myeloid-specific antibody in patients (pts) with advanced solid tumours

Suchergebnisse filtern